Bristol-Myers Squibb Reports Q3 Earnings Beat and Raises 2026 Revenue Guidance
Bristol-Myers Squibb (BMY) reported third-quarter financial results that exceeded market expectations, posting a non-GAAP earnings per share (EPS) of $1.35, which beat consensus by $0.13. Total revenue for the quarter reached $13.1 billion, representing a 7.2% increase year-over-year and surpassing estimates by $370 million. Following these strong results, the company has raised its full-year 2026 revenue guidance to a range of $49.75 billion to $50.25 billion. The updated non-GAAP EPS guidance for 2026 is now set between $6.35 and $6.55, accounting for a $0.60 per share net impact from acquired in-process research and development (IPRD) charges and licensing income.
Tickers: $BMY
Topics: earnings beat financial results guidance raise revenue growth